Sweden Sees Improvement in Estrogen Medication Supply Amid Healthcare Management Concerns

Sweden is witnessing a notable reduction in the longstanding shortage of estrogen medications, such as sprays, patches, and gels, a problem affecting approximately 380,000 women over 45 years old. This shortage, driven by increased demand and updated treatment guidelines, prompted government action in May when the Medical Products Agency (Läkemedelsverket) and the Dental and Pharmaceutical Benefits Agency (TLV) were tasked with improving supply. TLV's approval of higher prices aims to attract manufacturers to prioritize the Swedish market, despite potential cost implications for patients. Tina Crafoord, director at Läkemedelsverket, highlighted a clear trend reversal in availability, though sprays and patches remain somewhat scarce, with fuller improvements expected after the new year. Efforts also include better prescriber guidance on alternatives and a study into domestic production, facing challenges due to the complex manufacturing process of estrogen patches.

Concurrent with these pharmaceutical supply developments, concerns about healthcare access have been raised in Region Stockholm. Carl-Johan Schiller, healthcare regional councilor from the Christian Democrats, criticized the region's inability to establish new healthcare centers since 2008, attributing this to an over-reliance on market mechanisms. Schiller insists the region must reclaim an active role in healthcare provision to guarantee equitable access across Stockholm.

These dual issues reflect the complexities in Sweden's healthcare system, balancing medication supply and infrastructure management to meet public needs more effectively.